AI assistant
Orexo — Investor Presentation 2008
May 12, 2008
3093_rns_2008-05-12_d266ffaa-daf1-44ee-bfa3-79990a6715af.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Press release May 12, 2008
Orexo to present at BioEquity Europe 2008
Uppsala, Sweden - Orexo AB today announced that the company will present at the BioEquity Europe 2008 Conference on May 28.
The conference is being held on May 28-29 at Hotel Okura, Amsterdam, The Netherlands, and attracts investors from the European financial community. More information is found on www.biocentury.com/BCApp/BioCenturyCommon/BCConferences.aspx?ss=1
The slides from Orexo´s presentation will subsequently be available on www.orexo.com.
For further information, please contact:
Torbjörn Bjerke, President and CEO, Orexo AB Tel: +46 (0)708-66 19 90 E-mail: [email protected]
Claes Wenthzel, Executive Vice President & CFO, Orexo AB Tel: +46 (0)18-780 88 44 E-mail: [email protected]
TO THE EDITORS
About Orexo
Orexo is a pharmaceutical company, focusing on development of new, patented drugs by combining welldocumented substances with innovative technologies, and the development of new treatments for respiratory and inflammatory diseases.
Orexo has a broad and competitive late-stage product portfolio, including two marketed products, five products in clinical phase and two undergoing registration.
To date, Orexo have out-licensed the market rights for Rapinyl for the US, the EU and Japan markets, the worldwide market rights for Sublinox (OX22) and OX-NLA, and a out-license and research collaboration with Boehringer Ingelheim regarding the development of a new class of drugs to treat pain and inflammation. Also, Orexo has established a Nordic sales force by entering into a joint venture with ProStrakan.
Orexo has head office in Uppsala and is listed on the OMX Nordic Exchange Stockholm, Small Cap (ticker: ORX).
www.orexo.com